An analysis of C.difficile environmental contamination during and following treatment for C.difficile infection

An analysis of C.difficile environmental contamination during and following treatment for C.difficile infection

Background Lower C. difficile spore counts in faeces from C. difficile infection (CDI) patients treated with fidaxomicin vs vancomycin have been observed. We aimed to determine if environmental contamination is lower in patients treated with fidaxomicin compared with those treated with vancomycin/me...

Bibliografski detalji
Glavni autori:	Davies, K, Mawer, D, Walker, AS, Berry, C, Planche, T, Stanley, P, Goldenberg, S, Sandoe, J, Wilcox, MH
Format:	Journal article
Jezik:	English
Izdano:	Oxford University Press 2020

Slični predmeti

Differences in outcome according to Clostridium difficile testing method: A prospective multicentre diagnostic validation study of C difficile infection
od: Planche, T, i dr.
Izdano: (2013)

Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection.
od: Planche, T, i dr.
Izdano: (2013)

Fecal-free toxin detection remains the best way to detect Clostridium difficile infection
od: Planche, T, i dr.
Izdano: (2015)

Clostridium difficile mixed infection and reinfection.
od: Eyre, D, i dr.
Izdano: (2012)

Diverse sources of C. difficile infection identified on whole-genome sequencing.
od: Eyre, D, i dr.
Izdano: (2013)

Diverse sources of C. difficile infection identified on whole-genome sequencing
od: Eyre, D, i dr.
Izdano: (2013)

Epidemiology of Clostridium difficile in infants in Oxfordshire, UK: risk factors for colonization and carriage, and genetic overlap with regional C. difficile infection strains
od: Stoesser, N, i dr.
Izdano: (2017)

Regarding "Clostridium difficile ribotype does not predict severe infection".
od: Walker, A, i dr.
Izdano: (2013)

K-mer based prediction of Clostridioides difficile relatedness and ribotypes
od: Moore, M, i dr.
Izdano: (2022)

Patient and strain characteristics associated with Clostridium difficile transmission and adverse outcomes
od: Martin, J, i dr.
Izdano: (2018)

Risk factors for Clostridium difficile acquisition in infants: importance of study design.
od: Stoesser, N, i dr.
Izdano: (2013)

Immunization strategies for Clostridium difficile infections.
od: Rebeaud, F, i dr.
Izdano: (2012)

Comparison of control of Clostridium difficile infection in six English hospitals using whole-genome sequencing
od: Eyre, D, i dr.
Izdano: (2017)

Molecular epidemiology of Clostridium difficile strains in children compared with that of strains circulating in adults with Clostridium difficile-associated infection.
od: Stoesser, N, i dr.
Izdano: (2011)

Hash-based core genome multilocus sequencing typing for Clostridium difficile
od: Eyre, DW, i dr.
Izdano: (2019)

Clostridium difficile infection: clinico-epidemiological perspective.
od: SYUHADA N,, i dr.
Izdano: (2013)

Predictors of first recurrence of Clostridium difficile infection: implications for initial management.
od: Eyre, D, i dr.
Izdano: (2012)

Multilocus sequence typing of Clostridium difficile.
od: Griffiths, D, i dr.
Izdano: (2010)

Evolutionary history of the Clostridium difficile pathogenicity locus.
od: Dingle, K, i dr.
Izdano: (2014)

Effect of age on treatment outcomes in Clostridium difficile infection.
od: Louie, T, i dr.
Izdano: (2013)

Contribution to Clostridium difficile transmission of symptomatic patients with toxigenic strains who are fecal toxin negative
od: Mawer, D, i dr.
Izdano: (2017)

Effects of control interventions on Clostridium difficile infection in England: an observational study
od: Dingle, K, i dr.
Izdano: (2017)

Clinical Clostridium difficile: clonality and pathogenicity locus diversity.
od: Dingle, K, i dr.
Izdano: (2011)

Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection.
od: Walker, A, i dr.
Izdano: (2013)

In vitro activity of eravacycline against common ribotypes of Clostridioides difficile
od: Bassères, E, i dr.
Izdano: (2020)

Effect of Advancing Age on Outcomes of Therapy for Clostridium difficile Infection.
od: Louie, T, i dr.
Izdano: (2011)

Asymptomatic Clostridium difficile colonisation and onward transmission
od: Eyre, D, i dr.
Izdano: (2013)

Microevolutionary analysis of Clostridium difficile genomes to investigate transmission.
od: Didelot, X, i dr.
Izdano: (2012)

Microevolutionary analysis of Clostridium difficile genomes to investigate transmission
od: Didelot, X, i dr.
Izdano: (2012)

Surveillance of infection severity: a registry study of laboratory diagnosed Clostridium difficile.
od: Schlackow, I, i dr.
Izdano: (2012)

Fairness of financial penalties to improve control of Clostridium difficile.
od: Walker, A, i dr.
Izdano: (2008)

Fairness of financial penalties to improve control of Clostridium difficile.
od: Walker, A, i dr.
Izdano: (2008)

A review on the effects of probiotics and antibiotics towards Clostridium difficile infections
od: Azman, Hazirah, i dr.
Izdano: (2013)

Trends in incidence and clinical outcomes of Clostridioides difficile infection, Hong Kong
od: Guo, Cosmos L. T., i dr.
Izdano: (2022)

Risk factors and treatment outcomes of severe Clostridioides difficile infection in Singapore
od: Tay, Hui Lin, i dr.
Izdano: (2020)

Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
od: Cornely, O, i dr.
Izdano: (2012)

Clostridium difficile Associated Risk of Death Score (CARDS): A novel severity score to predict mortality among hospitalized patients with Clostridium difficile infection
od: Cribb Fabersunne, C., i dr.
Izdano: (2017)

Clostridium difficile surveillance: harnessing new technologies to control transmission.
od: Eyre, D, i dr.
Izdano: (2013)

The clinical and environmental spread and diversity of toxigenic Clostridium difficile diarrhea in the region of the Middle East.
od: N., Sadeghifard, i dr.
Izdano: (2010)

Gut metabolites predict Clostridioides difficile recurrence
od: Dawkins, Jennifer J., i dr.
Izdano: (2022)